BMRN vs. CRL: BioMarin Pharmaceutical vs. Charles River Laboratories Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while CRL is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

BioMarin Pharmaceutical (BMRN) at -18.55% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Charles River Laboratories (CRL) at 1.41 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both BioMarin Pharmaceutical (BMRN) at 0.67 and Charles River Laboratories (CRL) at 0.87 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither BioMarin Pharmaceutical (BMRN) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioMarin Pharmaceutical (BMRN) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both BioMarin Pharmaceutical (BMRN) at 1.73 and Charles River Laboratories (CRL) at 5.01 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics